A prospective randomized trial of α2B-Interferon/γ-Interferon or the combination in advanced metastatic renal cell carcinoma

K. Foon, J. Doroshow, E. Bonnem, A. Fefer, S. Graham, B. Grosh, P. Narayan, L. Elias, Harold Harvey, R. Schulof, R. Williams, J. Rinehart, P. Zekan, W. Catalona, R. Dillman, S. Salmon, F. Galasso

Research output: Contribution to journalArticle

39 Scopus citations

Abstract

Eighty-nine patients with advanced measurable metastatic renal cell carcinoma were entered into a prospective randomized trial comparing alpha-interferon to gamma-interferon and to the combination. The trial was performed in order to confirm the activity of gamma-interferon and assess the potential clinical synergism. Response rates were 5, 10, and 5%, respectively. The low response rate may have been due to the inability to raise the doses of the interferons to higher levels. Clinical synergy at this dose, route, and schedule of administration in renal cell carcinoma does not exist.

Original languageEnglish (US)
Pages (from-to)540-545
Number of pages6
JournalJournal of Biological Response Modifiers
Volume7
Issue number6
StatePublished - Dec 1988

All Science Journal Classification (ASJC) codes

  • Immunology
  • Pharmacology
  • Cancer Research

Fingerprint Dive into the research topics of 'A prospective randomized trial of α<sub>2B</sub>-Interferon/γ-Interferon or the combination in advanced metastatic renal cell carcinoma'. Together they form a unique fingerprint.

  • Cite this

    Foon, K., Doroshow, J., Bonnem, E., Fefer, A., Graham, S., Grosh, B., Narayan, P., Elias, L., Harvey, H., Schulof, R., Williams, R., Rinehart, J., Zekan, P., Catalona, W., Dillman, R., Salmon, S., & Galasso, F. (1988). A prospective randomized trial of α2B-Interferon/γ-Interferon or the combination in advanced metastatic renal cell carcinoma. Journal of Biological Response Modifiers, 7(6), 540-545.